Maxim's backloaded 2004

Maxim Pharmaceuticals Inc. reported last week that its Ceplene histamine dihydrochloride plus IL-2 significantly improved leukemia-free survival compared to no treatment (the standard of care) in a Phase III trial

Read the full 309 word article

How to gain access

Continue reading with a
two-week free trial.